GPC Biotech to Withdraw Marketing Application for Satraplatin
Posted on: Monday, 28 July 2008, 12:01 CDT
GPC Biotech has reported that the company has been informed by its partner for satraplatin in Europe that they plan to withdraw the marketing authorization application for satraplatin plus prednisone for the treatment of hormone-refractory prostate cancer patients whose prior chemotherapy has failed.
This decision was based on a list of outstanding issues received following review by the Committee for Medicinal Products for Human Use of the European Medicines Agency of the filing, which indicates that the opinion of the committee is that the application is currently not approvable based on the information provided.
Bernd Seizinger, CEO of GPC Biotech, said: "Although we previously communicated that the approval of the marketing authorization application for satraplatin would be challenging, today's outcome is nevertheless disappointing.
"We are working closely with our partners to determine the next steps regarding the development of satraplatin and continue to focus our other efforts on advancing our RGB-286638 kinase inhibitor into the clinic and exploring various merger and acquisition opportunities."
Source: Datamonitor
Related Articles
- GPC Biotech Launches Expanded Access Program for Oncology Drug Candidate Satraplatin in the U.S.
- Spectrum Pharmaceuticals Announces Positive Results of Satraplatin Pivotal Phase 3 Trial in Patients With Hormone-Refractory Prostate Cancer
- GPC Biotech Advances Satraplatin NDA
- Pharmion Announces Start of Phase 1 Trial Evaluating Satraplatin Plus Xeloda(R) in Patients With Advanced Solid Tumors
- Spectrum Pharmaceuticals Announces Presentation of New Satraplatin Pre-Clinical Data at AACR
- Spectrum Presents New Satraplatin Prostate Cancer Data
- Spectrum Pharmaceuticals Announces Presentation of New Satraplatin Clinical Data From Pharmacokinetics Study at ASCO Prostate Cancer Symposium
- Pharmion Corporation Announces New Satraplatin Clinical Data From Pharmacokinetics Study at ASCO Prostate Cancer Symposium
- Spectrum Issues Update on Satraplatin
- Spectrum Pharmaceuticals Announces Achievement of Target Enrollment in Satraplatin Phase 3 Registrational Trial (SPARC) for Second-Line Chemotherapy of Hormone Refractory Prostate Cancer
 |
 |
User Comments (0)
RSS Feeds